GMAB Stock Price and Chart — NASDAQ:GMAB — TradingView

Compare with Genmab A/S

Key facts today

Genmab (GMAB): Q3 2026 DARZALEX net sales $4.239B — $2.528B U.S., $1.711B ex-U.S. Genmab receives royalties from J&J under its DARZALEX license. No guidance change or new catalysts announced.

Analyze the impact Analyze the impact

Key stats

Upcoming earnings

Company info

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Financials

Performance

Revenue to profit conversion

Debt level and coverage

Earnings

Next:—

Ideas

Technical and Fundamental Assessment of Genmab Technical Analysis Genmab has been in an upward trend since the beginning of April 2025. The trend is only partly supported by the moving averages (MA) and is weakened by a declining RSI-21. The price is currently below or near the lower edge of a red Ichimoku cloud and is trading in the lower par

GMAB at a Critical Confluence Zone – Potential UP or down?GMAB at a Critical Confluence Zone – Potential Breakout or Reversal? GMAB has shown strong recovery momentum since its April 7th, 2025, low. The price is currently testing a significant confluence area formed by a descending trendline and the Fib 38.2% support level. If price action holds above th

GMAB - Top Fundamental Quality + Strong Uptrend **Title: GMAB - Top Fundamental Quality + Strong Uptrend | Long Entry $29.10** --- **📈 Ticker:** GMAB (Genmab A/S) **📍 Recommendation:** LONG **⏰ Timeframe:** Position Trade (2-8 weeks) --- ### **🎯 Trade Idea Summary** - **Entry:** $29.10 (on pullback to support) - **Stop Loss:** $25.99

by shortermtrader

Genmab 4h long Zone + 1st measured move PB. Could potentially go all the way up to the expanding triangle top?

GMAB / GENMAB / Likely this is the scenario The last 10 Years give us an idea how this stock moves. Today i bough some expecting around 20% profit until End of July. I look at Seasonality / seasonal price tendencies and identified a good period to be long in that stock. I have confidence in that and my entry was the break of yesterday candle.

by Amazing-Fractals

GENMAB Buy scenario I am loking to get into a buy at best after the downward trendline is broken and the SMA(89) is crossed to the upside afterwards. See examples in the past as indicated by my green circles... Leave a like or comment, please

by Amazing-Fractals

Watch out for long position in Genmab Genmab has reached an important area, which before in time have been a good time to start a long postion.

Genmap Correction -40 %I like Genmab. The stock was one of my long positions for many years. I went into cash in the fall of 2021. After minus 40 percent, I will now gradually add to Genmab again.

by Softclick-Capital

Genmab is a era done ?I have sold all of my genmab shares i started to buy at the start of corona, 5 year tmeframe i think we see a head an shoulder formation an hoping to buy again 15-1600 kr :)

by BulutBozkurt

in the stock Hello again, i bought this stock last year at like 1500 kr, but unf. i see a Head an should forming in think it will fall a little back, of course i hope im wrong an go up from here :) An not selling holding at least 5-20 years :)

by BulutBozkurt

See all ideas

Technicals

Summarizing what the indicators are suggesting.

Neutral

Neutral

Neutral

An aggregate view of professional's ratings.

Neutral

Neutral

Neutral

Seasonals

Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock

Weight1.50%

Market value‪160.76 M‬

Weight4.06%

Market value‪116.67 M‬

Weight0.10%

Market value‪18.88 M‬

Weight3.74%

Market value‪7.61 M‬

Weight0.24%

Market value‪3.04 M‬

Weight0.24%

Market value‪3.04 M‬

Weight0.26%

Market value‪2.58 M‬

Weight0.24%

Market value‪1.34 M‬

Weight0.09%

Market value‪1.01 M‬

Weight0.01%

Market value‪976.40 K‬

Weight2.50%

Market value‪896.88 K‬

Explore more ETFs